Evidence map›Paper›PMID 41037684›Full record

ArticleInternational journal of cancer2026

Integrated scFv identification and CAR T cell generation for AML targeting in vivo.

Yi Liu, Annika Lauk, David Sedloev, Josephine Brysting, Ela Cetin, Chunan Liu, Maximilian Mönnig, Thomas Luft, Haiyang Yun, Michael Schmitt and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yi LiuMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-4961-2660
Annika LaukMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
David SedloevMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Josephine BrystingMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Ela CetinMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Chunan LiuStructural and Molecular Biology, Division of Biosciences, University College London, London, UK.ORCID https://orcid.org/0000-0001-5957-4197
Maximilian MönnigMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Thomas LuftMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Haiyang YunMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Michael SchmittMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-1579-1509
Tim SauerMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Fengbiao ZhouMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Christian RohdeMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Carsten Müller-TidowMedical Faculty Heidelberg and Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.

Funding

Deutsche Forschungsgemeinschaft MU1328/23-1Deutsche Forschungsgemeinschaft SFB1709/12025-533056198Deutsche Forschungsgemeinschaft YU 406/1-1Deutsche José Carreras Leukämie-Stiftung 04R/2022Deutsche Krebshilfe 70113908Deutsche Krebshilfe 70115215Deutsche Krebshilfe SFB 1709Wilhelm-Sander-Stiftung 2021.145.1Wilhelm-Sander-Stiftung 2023.127.1
6 · The paper itself

Abstract

Cancer immunotherapy has witnessed remarkable advancements, particularly in the development of chimeric antigen receptor (CAR) T cell therapy. Here, we integrated single chain variable fragment (scFv) development with CAR T cell generation based on a newly developed scFv phagemid library. High-throughput long-read PacBio sequencing identified 4.5 × 10

Indexed as

Immunotherapy, AdoptiveLectins, C-TypeLeukemia, Myeloid, AcuteReceptors, Chimeric AntigenSingle-Chain AntibodiesT-LymphocytesAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred NODReceptors, MitogenXenograft Model Antitumor AssaysCLEC12A protein, humanLectins, C-TypeReceptors, Chimeric AntigenReceptors, MitogenSingle-Chain Antibodiesacute myeloid leukemiaCAR T cell therapyCLL1phage display libraryscFv

Identifiers

PMID41037684
PMCPMC12712367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.